Skip to main content
S 150 118th Congress Senate Health Administrative remedies Civil actions and liability Competition and antitrust Consumer affairs Drug safety, medical device, and laboratory regulation Federal Trade Commission (FTC) Health care costs and insurance Inflation and prices Intellectual property Judicial review and appeals Manufacturing Prescription drugs

Affordable Prescriptions for Patients Act of 2023

Introduced: April 9, 2024 Introduced by: Cornyn, John Republican · Texas See on congress.gov
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 11 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 15, 2024
Held at the desk.
Jul 15, 2024
Received in the House.
Jul 12, 2024
Message on Senate action sent to the House.
Jul 11, 2024
Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S4537-4538)
Jul 11, 2024
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.
Jul 11, 2024
Measure laid before Senate by unanimous consent. (consideration: CR S4537-4538)
Mar 1, 2023
Placed on Senate Legislative Calendar under General Orders. Calendar No. 22.
Mar 1, 2023
Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.
Feb 9, 2023
Committee on the Judiciary. Ordered to be reported without amendment favorably.
Jan 30, 2023
Read twice and referred to the Committee on the Judiciary.
Jan 30, 2023
Introduced in Senate
 Amendments to this bill 1

1 agreed to

AmendmentSponsorPurposeStatusLatest action
SAMDT 2,399 Cornyn, John In the nature of a substitute. Agreed to Jul 11, 2024
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Affordable Prescriptions for Patients Act of 2023

This bill limits in certain instances the number of patents that a reference biological product manufacturer can assert in a patent infringement lawsuit against a company seeking to sell a biosimilar version.

Specifically, if the biosimilar manufacturer completes certain actions as part of an abbreviated pathway to get market approval, the bill limits, subject to exceptions and waivers, the number of certain types of patents that the reference product manufacturer may assert, such as patents filed more than four years after the reference product received market approval.

 

 

What's happening now July 15, 2024

Held at the desk.

 Bill text 3 versions

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 20

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

See all 20 filings →
Cite this page click to expand
APA
U.S. Congress. (2026). S. 150: Affordable Prescriptions for Patients Act of 2023. 118th Congress. Open America. https://openamerica.io/bill/118-S-150/
MLA
"S. 150: Affordable Prescriptions for Patients Act of 2023." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-S-150/.
Bluebook (legal)
S. 150, 118th Cong. (2026), https://openamerica.io/bill/118-S-150/.
Markdown link
[S. 150: Affordable Prescriptions for Patients Act of 2023](https://openamerica.io/bill/118-S-150/)
Report a problem